Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria La...( Expanded Dermatology Division of Vale...),Health

Expanded Dermatology Division of Valeant Pharmaceuticals Introduces Fixed Combination Acne Treatment Designed to Increase Patient Satisfaction and Use

SAN FRANCISCO, March 6 /PRNewswire-FirstCall/ -- Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International (NYSE: VRX), announced today the commercial launch of Acanya(TM) Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) indicated for the once-daily treatment of acne vulgaris in patients 12 years and older.

Evaluated in clinical studies enrolling over 3,200 subjects with moderate to severe acne vulgaris, Acanya Gel is the only fixed combination antibiotic and benzoyl peroxide (BPO) medication FDA-approved for the once-daily treatment of both non-inflammatory and inflammatory lesions of acne.

In pivotal Phase III clinical trials, Acanya Gel showed superior efficacy to the vehicle gel and either individual active ingredient, while demonstrating excellent tolerability and very high patient satisfaction scores. Results of the 2,813-patient study were reported in the November issue of the Journal of the American Academy of Dermatology.

According to Diane Thiboutot, M.D., a Phase III trial investigator, "Use of combination therapy is recommended at the initiation of acne therapy to inhibit multiple pathogenic factors. The new fixed combination, Acanya Gel, is an effective, safe, and well-tolerated topical product for treating patients with moderate to severe inflammatory and non-inflammatory acne. In addition, high levels of patient satisfaction with Acanya Gel point to the potential for increased patient adherence to treatment, and thus, to improved clinical outcomes."

Phase III Clinical Results

Efficacy: Acanya Ge
'/>"/>